Confirming intrinsic pathway apoptosis event in cervical carcinoma cells (HeLa) treated with hybrid nanoliposomes
Cancer targeted nanotherapy represent an exciting field in the search for new cancer specific therapies to avoid conventional chemotherapy side effects. Because cancer cells usually have malfunctioning apoptotic machinery which favors survival pathways and drug resistance. Cancer cell apoptosis is the favorable event to be induced in any new anticancer agent development. Nanotherapy goals are to elevate therapeutic efficiency, selectivity, and overcome drug resistance as major obstacle in cancer treatment. Hybrid nanoliposomes (nHLs) may fulfill all these features in cancer therapeutics. We have previously demonstrated the ability of in house synthesized nHLs to inhibit HeLa cell line proliferation and study preliminary the induction of apoptosis as a consequences of that inhibition. In order to confirm the event of apoptosis in HeLa cell line incubated with the synthesized nHLs we exposed HeLa cells to inhibition concentration 50 (IC50) of previously synthesized hybrid nanoliposomes. Mechanism of apoptosis induction was determined using mitochondrial membrane potential disruption, caspase-3 activity and single cell gel electrophoresis as well as DNA fragmentation assay. All apoptosis detection procedures used gave a clear defined significant indication that nHLs was capable of induce apoptosis in HeLa cells through intrinsic pathway. This result needs further investigation to confirm nHLs as potential nanotherapy.